SlideShare a Scribd company logo
1 of 34
Download to read offline
TB and Diabetes:
Should all diabetics with
   TB be on insulin?
      Iris Thiele Isip Tan MD, FPCP, FPSEM
    Clinical Associate Professor, UP College of Medicine
 Section of Endocrinology, Diabetes & Metabolism, UP-PGH




                                 http://www.endocrine-witch.info
Insulin
for Diabetics
   with TB
1                           3
    Drug
   effects/                Indications
interactions                for insulin
                Insulin
 2             for Diabetics 4
                  with TB
 Immune                     Treatment
dysfunction                   goals
1                           3
    Drug
   effects/                Indications
interactions                for insulin
                Insulin
 2             for Diabetics 4
                  with TB
 Immune                     Treatment
dysfunction                   goals
Rifampicin: a potent Cyt P450 inducer
  lowers the serum levels of SU and metformin


                                       Guptan & Asha. Ind J Tub 2000
Placebo
                             Rifamipicin




Rifampicin can induce CYP2C9-mediated metabolism
   Modest reduction of plasma glimepiride concentration
        “probably of limited clinical significance”


                                      Niemi et al. Br J Clin Pharmacol 2000;50:591-595
Case report

62/M on chlorpropamide
250 mg daily
Given Rifampin
600 mg daily
Chlorpropamide
increased to 400 mg
daily




                         Self & Morris. Chest 1980
Case report

65/M on gliclazide 80 mg daily
FPG 6.4 mmol/L
HbA1c 5.4%
Atypical mycobacteriosis
Rifampicin, INH, EMB, Clarithromycin
FPG increased to 11.3 mmol/L
Gliclazide increased up to 160 mg daily
When rifampicin discontinued, gliclazide reduced to 80 mg
daily (HbA1c 5.6%)


                                          Sellers & Dean. Diabetes Care 2000
SU and
 Metformin
contraindicated
   in liver
   disease




  Drug-induced hepatitis with TB treatment
      Prevalence: 9.7% (Malaysia) & 12% (HK)
        Alcohol abuse and chronic hepatitis
            are independent risk factors
                                 Marzuki et al. Singapore Med J 2008;49(9):688
                                           Yew et al. Eu Resp J 1196;(9):389-90
Metformin can cause anorexia and GI discomfort
   1930’s case series: giving insulin for weight gain


                                         Photo from Seattle Municipal Archives
                                          Accessed from http://www.flickr.com
“The use of insulin to cause a gain in
weight in undernourished children and
 in lean but otherwise healthy adults is
  now a well-established procedure. It
   seems reasonable therefore to try its
    effects in undernourished persons
suffering from pulmonary tuberculosis.”
                              Heaton TG. Can Med Assoc J 1932;498-501
Conclusion
 “Insulin has a real place in the treatment of chronic
forms of pulmonary tuberculosis, febrile or afebrile, if
  the patient is undernourished. In some such cases
     insulin is the best drug treatment we have.”

                                       Heaton TG. Can Med Assoc J 1932;498-501
1                           3
    Drug
   effects/                Indications
interactions                for insulin
                Insulin
 2             for Diabetics 4
                  with TB
 Immune                     Treatment
dysfunction                   goals
1                           3
    Drug
   effects/                Indications
interactions                for insulin
                Insulin
 2             for Diabetics 4
                  with TB
 Immune                     Treatment
dysfunction                   goals
Immunologic abnormalities         Pulmonary physiologic
  in diabetes                       dysfunction
  Abnormal chemotaxis, adherence,
  phagocytosis and microbicidal     Diminished bronchial reactivity
  function of PMNs
  Decreased peripheral monocytes    Reduced elastic recoil and lung
  with impaired phagocytosis        volumes
  Poor blast transformation of
                                    Reduced diffusion capacity
  lymphocytes
                                    Occult mucus plugging of
  Defective C3 opsonic function
                                    airways
                                    Reduced ventilatory response
                                    to hypoxemia
 Worsened by
hyperglycemia


                                                      Guptan & Shah. Ind J Tub 2000
TB infection produces
glucose intolerance that
improves or normalizes
   with TB treatment

      Not specific to TB,
   also seen in pneumonia




                            Jawad et al. J Pakistan Med Assoc 1995;45(9):237-8
n=496




Mycobacterial clearance from sputum is delayed during the
    first phase of treatment in patients with diabetes
    Diabetes: independent risk factor for a 5-delay in
      mycobacterial clearance within first 60 days
                                  Restrepo et al. Am J Trop Med Hyg 2008;79(4):541-4
Diabetes increased risk of
active pulmonary TB only in
     those with HbA1c >7%

           Active Adj HR 3.11
     [95%CI 1.63-5.92, p =0.001)
 Culture confirmed Adj HR 3.08
     [95%CI 1.44-6.57, p =0.004)
       Pulmonary Adj HR 3.11
     [95%CI 1.79-7.33, p <0.001)



                                   Leung et al. Am J Epid 20008;167:1486-94
Diabetics had 6.5x
  higher odds [95%CI 1.1-3.80,
  p=0.039] of dying from TB
     than non-diabetics
   Relationship between severity
   of diabetes and TB outcomes
       could not be evaluated

Unclear if tight diabetes control would
  have a positive impact on treatment
    outcomes of those with active TB

                                          Dooley et al. Am J Trop Med Hyg 20009;80(4):634-9
Qing Zhang et al. Jpn J Infect Dis 20009;62:390-391
Qing Zhang et al. Jpn J Infect Dis 2009;62:390-391
1                           3
    Drug
   effects/                Indications
interactions                for insulin
                Insulin
 2             for Diabetics 4
                  with TB
 Immune                     Treatment
dysfunction                   goals
1                           3
    Drug
   effects/                Indications
interactions                for insulin
                Insulin
 2             for Diabetics 4
                  with TB
 Immune                     Treatment
dysfunction                   goals
Management of Coexistent TB and DM


Patients with poor diabetic control should be
hospitalized for stabilizing their blood sugar level.

Ideally, insulin should be used to control blood sugar
levels.

Oral hypoglycemics should be used only in cases of
mild diabetes. Drug interaction with rifampicin should
be kept in mind.

Goals of therapy: FPG 120 mg/dL and HbA1c <7%

                                             Guptan & Shah. Ind J Tub 2000
Indications for insulin in type 2 diabetes with TB



 Chronic and severe tuberculosis infection
 Loss of tissue and function of pancreas
 Requirement of high calorie, high protein diet
 Interactions and adverse effects of anti-TB drugs
 Associated hepatic disease
 Contraindications for oral antidiabetic drugs
 Aging

                                           Rao PV. Int J Diab Dev Countries 1999
Brazilian
 Thoracic
Association
   2009
                  TB in Diabetics
“Consider extending treatment to 9 months and replace
oral hypoglycemic agents with insulin during treatment
         (keep fasting glycemia <160 mg/dL).”



                         BTA Committee on Tuberculosis & BTA Tuberculosis Working Group
                                                  J Bras Pneumol 2009;35(10):1018-1048
Who should be started on insulin?




On Metformin with A1c >8.5%
Not reaching A1c target of OHA combination therapy
Kidney/liver dysfunction where OHA is contraindicated
Severe uncontrolled diabetes with catabolism


                            ADA-EASD 2008 Algorithm. Diabetes Care 31:1-11, 2008
Who should be immediately started on insulin?




 Severely uncontrolled diabetes with catabolism
 Fasting BG >13.9 mmol/L (250 mg/dL)
 Random BG consistently > 16.7 mmol/L (300 mg/dL)
 A1c > 10%
 Presence of ketonuria
 Symptomatic diabetes: polyuria, polydipsia, weight loss

                              ADA-EASD 2008 Algorithm. Diabetes Care 31:1-11, 2008
1                           3
    Drug
   effects/                Indications
interactions                for insulin
                Insulin
 2             for Diabetics 4
                  with TB
 Immune                     Treatment
dysfunction                   goals
1                           3
    Drug
   effects/                Indications
interactions                for insulin
                Insulin
 2             for Diabetics 4
                  with TB
 Immune                     Treatment
dysfunction                   goals
Glycemic Targets for Type 2 Diabetes

                                                                                                         ADA-
                             Healthy          ADA 1            AACE 3               IDF    4
                                                                                                        EASD 5
     Hba1c (%)*                <6.0 1         <7.0 +             <6.5                <6.5                <7.0 +
     FBG, mmol/L              <5.6 2         5.0-7.2             <6.0               <6.0                 3.9-7.2
     (mg/dL)                  (<100)        (90-130)            (<110)             (<110)               (70-130)
     PPBG, mmol/L             <7.8**2                            <7.8              <8.0**                <10
                                             <10.0**
     (mg/dL)                  (<140)                            (<140)             (<145)               (<180)
     *DCCT-referenced assays: normal range 4–6%; **1–2 hours postprandial. †ADA and ADA/EASD guidelines
     recommend HbA1C levels ‘as close to normal (<6%) as possible without significant hypoglycemia’1,5
     ADA=American Diabetes Association; AACE=American Association of Clinical
     Endocrinologists;IDF=International Diabetes Federation; EASD=European Association for the Study of
     Diabetes.
1. 1 American Diabetes Association. Diabetes Care 2006;29(suppl 1):S4–S42.
2. 2 American Diabetes Association. Diabetes Care 2006;29(suppl 1):S43–8.

3. 3 American Association of Clinical Endocrinologists. Endocr Pract 2002;8(suppl 1):40–82.

4. 4 International Diabetes Federation. Global Guideline for Type 2 Diabetes. Brussels: International
   Diabetes Federation, 2005. http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf.
5. 5 Nathan D. et al. Diabetologia 2006;49:1711–21.
Expected Decrease in A1c

Step 1: initial                              9.0
                                                            Basal insulin
•Lifestyle change: 1-2%                      8.5
                                                               SU TZD
•Metformin: 1.5%                             8.0
Step 2: additional therapy                   7.5
•Basal insulin: 1.5-2.5% (at least)          7.0
•Sulfonylureas: 1.5%                         6.5
•TZDs: 0.5-1.4%                              6.0
•GLP-1 agonist: 0.5-1.0%                  HbA1c

                                      ADA-EASD Consensus. Nathan et al Diabetes Care 2006
1                           3
    Drug
   effects/                Indications
interactions                for insulin
                Insulin
 2             for Diabetics 4
                  with TB
 Immune                     Treatment
dysfunction                   goals
Thank You!
http://www.endocrine-witch.info

More Related Content

What's hot

Diabetes & treatment
Diabetes & treatment Diabetes & treatment
Diabetes & treatment
Biochemist Mohamed Kordy El-Gebaly
 

What's hot (20)

Hereditary angioedema
Hereditary angioedemaHereditary angioedema
Hereditary angioedema
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Incretins In Diabetes Mellitus
Incretins In Diabetes MellitusIncretins In Diabetes Mellitus
Incretins In Diabetes Mellitus
 
Torch infection
Torch infectionTorch infection
Torch infection
 
Dapagliflozin
DapagliflozinDapagliflozin
Dapagliflozin
 
Tb hiv-coinfection
Tb hiv-coinfectionTb hiv-coinfection
Tb hiv-coinfection
 
Tuberculosis update
Tuberculosis updateTuberculosis update
Tuberculosis update
 
Antitubercular agents in TB patients with Chronic Liver disease (CLD)
Antitubercular agents in TB patients with Chronic Liver disease (CLD)Antitubercular agents in TB patients with Chronic Liver disease (CLD)
Antitubercular agents in TB patients with Chronic Liver disease (CLD)
 
CTD-ILD.pptx
CTD-ILD.pptxCTD-ILD.pptx
CTD-ILD.pptx
 
Management of tb in ckd dr Tareq tantawy
Management of tb in ckd dr Tareq tantawyManagement of tb in ckd dr Tareq tantawy
Management of tb in ckd dr Tareq tantawy
 
Type 2 dm gdm new updates & guidelines
Type 2 dm  gdm new updates & guidelinesType 2 dm  gdm new updates & guidelines
Type 2 dm gdm new updates & guidelines
 
GLP1 Role : DM type 2
GLP1 Role : DM type 2GLP1 Role : DM type 2
GLP1 Role : DM type 2
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
History of tb
History of tbHistory of tb
History of tb
 
Hereditary angioedema
Hereditary angioedemaHereditary angioedema
Hereditary angioedema
 
Tuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM FoundationTuberculosis Treatment Symposia - The CRUDEM Foundation
Tuberculosis Treatment Symposia - The CRUDEM Foundation
 
RUBELLA
RUBELLARUBELLA
RUBELLA
 
RNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended versionRNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended version
 
Diabetes & treatment
Diabetes & treatment Diabetes & treatment
Diabetes & treatment
 
Shorter oral bedaquiline regimen 2022 NTEP guidelines
Shorter oral bedaquiline regimen 2022 NTEP guidelinesShorter oral bedaquiline regimen 2022 NTEP guidelines
Shorter oral bedaquiline regimen 2022 NTEP guidelines
 

Viewers also liked

Diabetes tipo 2 y tuberculosis pulmonar
Diabetes tipo 2 y tuberculosis pulmonarDiabetes tipo 2 y tuberculosis pulmonar
Diabetes tipo 2 y tuberculosis pulmonar
Raven Anfetamina
 
Binomio Tuberculosis-Diabetes
Binomio Tuberculosis-DiabetesBinomio Tuberculosis-Diabetes
Binomio Tuberculosis-Diabetes
Rita War
 
Tuberculosis y diabetes mellitus
Tuberculosis y diabetes mellitusTuberculosis y diabetes mellitus
Tuberculosis y diabetes mellitus
TbNuevoLeon
 
Dispatches Winter16
Dispatches Winter16Dispatches Winter16
Dispatches Winter16
Marcus Dunk
 
Dispatches Winter 16 pullout
Dispatches Winter 16 pulloutDispatches Winter 16 pullout
Dispatches Winter 16 pullout
Marcus Dunk
 
Estrategias para el abordaje de la tb y sus comorb
Estrategias para el abordaje de la tb y sus comorbEstrategias para el abordaje de la tb y sus comorb
Estrategias para el abordaje de la tb y sus comorb
TbNuevoLeon
 
Impact of DM and its control on the risk of developing TB in Taiwan
Impact of DM and its control on the risk of developing TB in TaiwanImpact of DM and its control on the risk of developing TB in Taiwan
Impact of DM and its control on the risk of developing TB in Taiwan
Ming Chia Lee
 

Viewers also liked (15)

Tuberculosis and diabetes mellitus double trouble
Tuberculosis and diabetes mellitus double troubleTuberculosis and diabetes mellitus double trouble
Tuberculosis and diabetes mellitus double trouble
 
TB with DM; A double edged sword!
TB with DM; A double edged sword!TB with DM; A double edged sword!
TB with DM; A double edged sword!
 
Diabetes and tuberculosis, An Unholy Alliance
Diabetes and tuberculosis, An Unholy AllianceDiabetes and tuberculosis, An Unholy Alliance
Diabetes and tuberculosis, An Unholy Alliance
 
HIV/Diabetes/TB Toolkit
HIV/Diabetes/TB ToolkitHIV/Diabetes/TB Toolkit
HIV/Diabetes/TB Toolkit
 
Diabetes tipo 2 y tuberculosis pulmonar
Diabetes tipo 2 y tuberculosis pulmonarDiabetes tipo 2 y tuberculosis pulmonar
Diabetes tipo 2 y tuberculosis pulmonar
 
Binomio Tuberculosis-Diabetes
Binomio Tuberculosis-DiabetesBinomio Tuberculosis-Diabetes
Binomio Tuberculosis-Diabetes
 
Tuberculosis y diabetes mellitus
Tuberculosis y diabetes mellitusTuberculosis y diabetes mellitus
Tuberculosis y diabetes mellitus
 
Dispatches Winter16
Dispatches Winter16Dispatches Winter16
Dispatches Winter16
 
Dispatches Winter 16 pullout
Dispatches Winter 16 pulloutDispatches Winter 16 pullout
Dispatches Winter 16 pullout
 
Cerebral malaria
Cerebral malariaCerebral malaria
Cerebral malaria
 
Estrategias para el abordaje de la tb y sus comorb
Estrategias para el abordaje de la tb y sus comorbEstrategias para el abordaje de la tb y sus comorb
Estrategias para el abordaje de la tb y sus comorb
 
Impact of DM and its control on the risk of developing TB in Taiwan
Impact of DM and its control on the risk of developing TB in TaiwanImpact of DM and its control on the risk of developing TB in Taiwan
Impact of DM and its control on the risk of developing TB in Taiwan
 
Epidemiology of diabetes mellitus
Epidemiology of diabetes mellitusEpidemiology of diabetes mellitus
Epidemiology of diabetes mellitus
 
4. prediabetes magnitud del problema
4. prediabetes    magnitud del problema4. prediabetes    magnitud del problema
4. prediabetes magnitud del problema
 
Diabetes ppt
Diabetes pptDiabetes ppt
Diabetes ppt
 

Similar to Should all diabetics with TB be on insulin?

Underlying pathophysiology in diabetes
Underlying pathophysiology in diabetesUnderlying pathophysiology in diabetes
Underlying pathophysiology in diabetes
Dr. Lin
 
Ueda2015 lilly.the art of insulin dr.mesbah sayed
Ueda2015 lilly.the art of insulin dr.mesbah sayedUeda2015 lilly.the art of insulin dr.mesbah sayed
Ueda2015 lilly.the art of insulin dr.mesbah sayed
ueda2015
 

Similar to Should all diabetics with TB be on insulin? (20)

Nutrition and Inflammation in CKD
Nutrition and Inflammation in CKD Nutrition and Inflammation in CKD
Nutrition and Inflammation in CKD
 
Glp1 clinical view
Glp1 clinical viewGlp1 clinical view
Glp1 clinical view
 
How To Change Treatment from OAD to Insulin in Type 2 DM .pptx
How To Change Treatment from OAD to Insulin in Type 2 DM .pptxHow To Change Treatment from OAD to Insulin in Type 2 DM .pptx
How To Change Treatment from OAD to Insulin in Type 2 DM .pptx
 
RSSDI
RSSDI RSSDI
RSSDI
 
Diabetes and new anti diabetic drugs
Diabetes and new anti diabetic drugsDiabetes and new anti diabetic drugs
Diabetes and new anti diabetic drugs
 
12- DM for Undergraduate.ppt
12- DM for Undergraduate.ppt12- DM for Undergraduate.ppt
12- DM for Undergraduate.ppt
 
Underlying pathophysiology in diabetes
Underlying pathophysiology in diabetesUnderlying pathophysiology in diabetes
Underlying pathophysiology in diabetes
 
2018 DM medicines
2018 DM medicines2018 DM medicines
2018 DM medicines
 
Modern therapy in diabetics with cad scintic day
Modern therapy in diabetics  with cad scintic dayModern therapy in diabetics  with cad scintic day
Modern therapy in diabetics with cad scintic day
 
RABBIT 2
RABBIT 2RABBIT 2
RABBIT 2
 
Ueda2015 lilly.the art of insulin dr.mesbah sayed
Ueda2015 lilly.the art of insulin dr.mesbah sayedUeda2015 lilly.the art of insulin dr.mesbah sayed
Ueda2015 lilly.the art of insulin dr.mesbah sayed
 
Dilemma of Treating Diabetes in CKD
Dilemma of Treating Diabetes in CKDDilemma of Treating Diabetes in CKD
Dilemma of Treating Diabetes in CKD
 
GLP1 ANALOGUES- BEYOND DIABETES.pptx
GLP1 ANALOGUES- BEYOND DIABETES.pptxGLP1 ANALOGUES- BEYOND DIABETES.pptx
GLP1 ANALOGUES- BEYOND DIABETES.pptx
 
Role of metformin in dm2 &amp; glibenclamide combination
Role of metformin in dm2 &amp; glibenclamide combinationRole of metformin in dm2 &amp; glibenclamide combination
Role of metformin in dm2 &amp; glibenclamide combination
 
Msd Orissa Apicon Nov 2008 Dr Ka
Msd Orissa Apicon Nov 2008 Dr KaMsd Orissa Apicon Nov 2008 Dr Ka
Msd Orissa Apicon Nov 2008 Dr Ka
 
ueda2012 nutrition in diabetes-d.bh
ueda2012 nutrition in diabetes-d.bhueda2012 nutrition in diabetes-d.bh
ueda2012 nutrition in diabetes-d.bh
 
Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...
Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...
Newer Anti-Hyperglycemic agents in type 2 Diabetes Mellitus e Expanding the h...
 
Imeglmin Slides agents in Types 2 Diabetes Mellitus
Imeglmin Slides agents in Types 2 Diabetes MellitusImeglmin Slides agents in Types 2 Diabetes Mellitus
Imeglmin Slides agents in Types 2 Diabetes Mellitus
 
Role of early basal insulin initiation of t2 dm
Role of early basal insulin initiation of t2 dmRole of early basal insulin initiation of t2 dm
Role of early basal insulin initiation of t2 dm
 
Role of early basal insulin initiation of t2 dm
Role of early basal insulin initiation of t2 dmRole of early basal insulin initiation of t2 dm
Role of early basal insulin initiation of t2 dm
 

More from Iris Thiele Isip-Tan

More from Iris Thiele Isip-Tan (20)

Artificial Intelligence and Health Research
Artificial Intelligence and Health ResearchArtificial Intelligence and Health Research
Artificial Intelligence and Health Research
 
AI in Pediatrics: Taking Baby Steps in the Big World of Data
AI in Pediatrics: Taking Baby Steps in the Big World of DataAI in Pediatrics: Taking Baby Steps in the Big World of Data
AI in Pediatrics: Taking Baby Steps in the Big World of Data
 
Artificial Intelligence in Health Professions Education
Artificial Intelligence in Health Professions EducationArtificial Intelligence in Health Professions Education
Artificial Intelligence in Health Professions Education
 
Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes Management
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
 
Artificial Intelligence in Biology Research and Instruction
Artificial Intelligence in Biology Research and InstructionArtificial Intelligence in Biology Research and Instruction
Artificial Intelligence in Biology Research and Instruction
 
Artificial Intelligence in Health and Research
Artificial Intelligence in Health and ResearchArtificial Intelligence in Health and Research
Artificial Intelligence in Health and Research
 
Artificial Intelligence: Ethical Issues in Residency Training
Artificial Intelligence: Ethical Issues in Residency TrainingArtificial Intelligence: Ethical Issues in Residency Training
Artificial Intelligence: Ethical Issues in Residency Training
 
Use of AI: Misinformation on Social Media
Use of AI: Misinformation on Social MediaUse of AI: Misinformation on Social Media
Use of AI: Misinformation on Social Media
 
Blended Learning: Strategies for Student Engagement
Blended Learning: Strategies for Student EngagementBlended Learning: Strategies for Student Engagement
Blended Learning: Strategies for Student Engagement
 
EMR Documentation: Challenges and Opportunities
EMR Documentation: Challenges and Opportunities EMR Documentation: Challenges and Opportunities
EMR Documentation: Challenges and Opportunities
 
How EMRs Improve Patient Management
How EMRs Improve Patient Management How EMRs Improve Patient Management
How EMRs Improve Patient Management
 
AI in Healthcare: Risks, Challenges, Benefits
AI in Healthcare: Risks, Challenges, BenefitsAI in Healthcare: Risks, Challenges, Benefits
AI in Healthcare: Risks, Challenges, Benefits
 
Social Media: Navigating the Ethics of Influence on Public Trust
Social Media: Navigating the Ethics of Influence on Public Trust Social Media: Navigating the Ethics of Influence on Public Trust
Social Media: Navigating the Ethics of Influence on Public Trust
 
Artificial Intelligence in Healthcare: Risks, Challenges, and Benefits
Artificial Intelligence in Healthcare: Risks, Challenges, and Benefits Artificial Intelligence in Healthcare: Risks, Challenges, and Benefits
Artificial Intelligence in Healthcare: Risks, Challenges, and Benefits
 
Gamification: Gen Z Teaching & Learning
Gamification: Gen Z Teaching & LearningGamification: Gen Z Teaching & Learning
Gamification: Gen Z Teaching & Learning
 
Telepediatrics: Moving Toward Usual Care
Telepediatrics: Moving Toward Usual Care Telepediatrics: Moving Toward Usual Care
Telepediatrics: Moving Toward Usual Care
 
Role of Social Media in Healthcare: An Internist's Perspective
Role of Social Media in Healthcare: An Internist's PerspectiveRole of Social Media in Healthcare: An Internist's Perspective
Role of Social Media in Healthcare: An Internist's Perspective
 
Digitalizing Education: Teaching for Transformation of Healthcare Professionals
Digitalizing Education: Teaching for Transformation of Healthcare ProfessionalsDigitalizing Education: Teaching for Transformation of Healthcare Professionals
Digitalizing Education: Teaching for Transformation of Healthcare Professionals
 
Jamboards, Digital Escape Rooms and ChatGPT
Jamboards, Digital Escape Rooms and ChatGPTJamboards, Digital Escape Rooms and ChatGPT
Jamboards, Digital Escape Rooms and ChatGPT
 

Recently uploaded

THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
DR SETH JOTHAM
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
MedicoseAcademics
 

Recently uploaded (20)

Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.GawadHemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
 
Dermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfDermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdf
 
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...
 
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communications
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
Pharmacology of drugs acting on Renal System.pdf
Pharmacology of drugs acting on Renal System.pdfPharmacology of drugs acting on Renal System.pdf
Pharmacology of drugs acting on Renal System.pdf
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
Presentació "Advancing Emergency Medicine Education through Virtual Reality"
Presentació "Advancing Emergency Medicine Education through Virtual Reality"Presentació "Advancing Emergency Medicine Education through Virtual Reality"
Presentació "Advancing Emergency Medicine Education through Virtual Reality"
 
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
 
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHYTUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
 
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
 
5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials
5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials
5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials
 

Should all diabetics with TB be on insulin?

  • 1. TB and Diabetes: Should all diabetics with TB be on insulin? Iris Thiele Isip Tan MD, FPCP, FPSEM Clinical Associate Professor, UP College of Medicine Section of Endocrinology, Diabetes & Metabolism, UP-PGH http://www.endocrine-witch.info
  • 3. 1 3 Drug effects/ Indications interactions for insulin Insulin 2 for Diabetics 4 with TB Immune Treatment dysfunction goals
  • 4. 1 3 Drug effects/ Indications interactions for insulin Insulin 2 for Diabetics 4 with TB Immune Treatment dysfunction goals
  • 5. Rifampicin: a potent Cyt P450 inducer lowers the serum levels of SU and metformin Guptan & Asha. Ind J Tub 2000
  • 6. Placebo Rifamipicin Rifampicin can induce CYP2C9-mediated metabolism Modest reduction of plasma glimepiride concentration “probably of limited clinical significance” Niemi et al. Br J Clin Pharmacol 2000;50:591-595
  • 7. Case report 62/M on chlorpropamide 250 mg daily Given Rifampin 600 mg daily Chlorpropamide increased to 400 mg daily Self & Morris. Chest 1980
  • 8. Case report 65/M on gliclazide 80 mg daily FPG 6.4 mmol/L HbA1c 5.4% Atypical mycobacteriosis Rifampicin, INH, EMB, Clarithromycin FPG increased to 11.3 mmol/L Gliclazide increased up to 160 mg daily When rifampicin discontinued, gliclazide reduced to 80 mg daily (HbA1c 5.6%) Sellers & Dean. Diabetes Care 2000
  • 9. SU and Metformin contraindicated in liver disease Drug-induced hepatitis with TB treatment Prevalence: 9.7% (Malaysia) & 12% (HK) Alcohol abuse and chronic hepatitis are independent risk factors Marzuki et al. Singapore Med J 2008;49(9):688 Yew et al. Eu Resp J 1196;(9):389-90
  • 10. Metformin can cause anorexia and GI discomfort 1930’s case series: giving insulin for weight gain Photo from Seattle Municipal Archives Accessed from http://www.flickr.com
  • 11. “The use of insulin to cause a gain in weight in undernourished children and in lean but otherwise healthy adults is now a well-established procedure. It seems reasonable therefore to try its effects in undernourished persons suffering from pulmonary tuberculosis.” Heaton TG. Can Med Assoc J 1932;498-501
  • 12. Conclusion “Insulin has a real place in the treatment of chronic forms of pulmonary tuberculosis, febrile or afebrile, if the patient is undernourished. In some such cases insulin is the best drug treatment we have.” Heaton TG. Can Med Assoc J 1932;498-501
  • 13. 1 3 Drug effects/ Indications interactions for insulin Insulin 2 for Diabetics 4 with TB Immune Treatment dysfunction goals
  • 14. 1 3 Drug effects/ Indications interactions for insulin Insulin 2 for Diabetics 4 with TB Immune Treatment dysfunction goals
  • 15. Immunologic abnormalities Pulmonary physiologic in diabetes dysfunction Abnormal chemotaxis, adherence, phagocytosis and microbicidal Diminished bronchial reactivity function of PMNs Decreased peripheral monocytes Reduced elastic recoil and lung with impaired phagocytosis volumes Poor blast transformation of Reduced diffusion capacity lymphocytes Occult mucus plugging of Defective C3 opsonic function airways Reduced ventilatory response to hypoxemia Worsened by hyperglycemia Guptan & Shah. Ind J Tub 2000
  • 16. TB infection produces glucose intolerance that improves or normalizes with TB treatment Not specific to TB, also seen in pneumonia Jawad et al. J Pakistan Med Assoc 1995;45(9):237-8
  • 17. n=496 Mycobacterial clearance from sputum is delayed during the first phase of treatment in patients with diabetes Diabetes: independent risk factor for a 5-delay in mycobacterial clearance within first 60 days Restrepo et al. Am J Trop Med Hyg 2008;79(4):541-4
  • 18. Diabetes increased risk of active pulmonary TB only in those with HbA1c >7% Active Adj HR 3.11 [95%CI 1.63-5.92, p =0.001) Culture confirmed Adj HR 3.08 [95%CI 1.44-6.57, p =0.004) Pulmonary Adj HR 3.11 [95%CI 1.79-7.33, p <0.001) Leung et al. Am J Epid 20008;167:1486-94
  • 19. Diabetics had 6.5x higher odds [95%CI 1.1-3.80, p=0.039] of dying from TB than non-diabetics Relationship between severity of diabetes and TB outcomes could not be evaluated Unclear if tight diabetes control would have a positive impact on treatment outcomes of those with active TB Dooley et al. Am J Trop Med Hyg 20009;80(4):634-9
  • 20. Qing Zhang et al. Jpn J Infect Dis 20009;62:390-391
  • 21. Qing Zhang et al. Jpn J Infect Dis 2009;62:390-391
  • 22. 1 3 Drug effects/ Indications interactions for insulin Insulin 2 for Diabetics 4 with TB Immune Treatment dysfunction goals
  • 23. 1 3 Drug effects/ Indications interactions for insulin Insulin 2 for Diabetics 4 with TB Immune Treatment dysfunction goals
  • 24. Management of Coexistent TB and DM Patients with poor diabetic control should be hospitalized for stabilizing their blood sugar level. Ideally, insulin should be used to control blood sugar levels. Oral hypoglycemics should be used only in cases of mild diabetes. Drug interaction with rifampicin should be kept in mind. Goals of therapy: FPG 120 mg/dL and HbA1c <7% Guptan & Shah. Ind J Tub 2000
  • 25. Indications for insulin in type 2 diabetes with TB Chronic and severe tuberculosis infection Loss of tissue and function of pancreas Requirement of high calorie, high protein diet Interactions and adverse effects of anti-TB drugs Associated hepatic disease Contraindications for oral antidiabetic drugs Aging Rao PV. Int J Diab Dev Countries 1999
  • 26. Brazilian Thoracic Association 2009 TB in Diabetics “Consider extending treatment to 9 months and replace oral hypoglycemic agents with insulin during treatment (keep fasting glycemia <160 mg/dL).” BTA Committee on Tuberculosis & BTA Tuberculosis Working Group J Bras Pneumol 2009;35(10):1018-1048
  • 27. Who should be started on insulin? On Metformin with A1c >8.5% Not reaching A1c target of OHA combination therapy Kidney/liver dysfunction where OHA is contraindicated Severe uncontrolled diabetes with catabolism ADA-EASD 2008 Algorithm. Diabetes Care 31:1-11, 2008
  • 28. Who should be immediately started on insulin? Severely uncontrolled diabetes with catabolism Fasting BG >13.9 mmol/L (250 mg/dL) Random BG consistently > 16.7 mmol/L (300 mg/dL) A1c > 10% Presence of ketonuria Symptomatic diabetes: polyuria, polydipsia, weight loss ADA-EASD 2008 Algorithm. Diabetes Care 31:1-11, 2008
  • 29. 1 3 Drug effects/ Indications interactions for insulin Insulin 2 for Diabetics 4 with TB Immune Treatment dysfunction goals
  • 30. 1 3 Drug effects/ Indications interactions for insulin Insulin 2 for Diabetics 4 with TB Immune Treatment dysfunction goals
  • 31. Glycemic Targets for Type 2 Diabetes ADA- Healthy ADA 1 AACE 3 IDF 4 EASD 5 Hba1c (%)* <6.0 1 <7.0 + <6.5 <6.5 <7.0 + FBG, mmol/L <5.6 2 5.0-7.2 <6.0 <6.0 3.9-7.2 (mg/dL) (<100) (90-130) (<110) (<110) (70-130) PPBG, mmol/L <7.8**2 <7.8 <8.0** <10 <10.0** (mg/dL) (<140) (<140) (<145) (<180) *DCCT-referenced assays: normal range 4–6%; **1–2 hours postprandial. †ADA and ADA/EASD guidelines recommend HbA1C levels ‘as close to normal (<6%) as possible without significant hypoglycemia’1,5 ADA=American Diabetes Association; AACE=American Association of Clinical Endocrinologists;IDF=International Diabetes Federation; EASD=European Association for the Study of Diabetes. 1. 1 American Diabetes Association. Diabetes Care 2006;29(suppl 1):S4–S42. 2. 2 American Diabetes Association. Diabetes Care 2006;29(suppl 1):S43–8. 3. 3 American Association of Clinical Endocrinologists. Endocr Pract 2002;8(suppl 1):40–82. 4. 4 International Diabetes Federation. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005. http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. 5. 5 Nathan D. et al. Diabetologia 2006;49:1711–21.
  • 32. Expected Decrease in A1c Step 1: initial 9.0 Basal insulin •Lifestyle change: 1-2% 8.5 SU TZD •Metformin: 1.5% 8.0 Step 2: additional therapy 7.5 •Basal insulin: 1.5-2.5% (at least) 7.0 •Sulfonylureas: 1.5% 6.5 •TZDs: 0.5-1.4% 6.0 •GLP-1 agonist: 0.5-1.0% HbA1c ADA-EASD Consensus. Nathan et al Diabetes Care 2006
  • 33. 1 3 Drug effects/ Indications interactions for insulin Insulin 2 for Diabetics 4 with TB Immune Treatment dysfunction goals